Weill Medical College of Cornell University

1. Regeneron Pharmaceuticals, Inc. $4,819,969 317 payments
2. Merck Sharp & Dohme Corporation $4,247,148 28 payments
3. Boehringer Ingelheim Pharmaceuticals, Inc. $2,591,890 64 payments
4. Pfizer Inc. $2,120,603 193 payments
5. Edwards Lifesciences Corporation $2,050,418 185 payments
6. Genentech, Inc. $1,868,253 136 payments
7. Celgene Corporation $1,398,779 66 payments
8. Abbott Laboratories $1,260,678 188 payments
9. Sanofi US Services Inc. $1,088,476 33 payments
10. Otsuka Pharmaceutical Co., Ltd. $1,045,064 27 payments

1. Multicenter, Randomized Phase II study evaluating Pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma $1,809,125 4 payments
2. Post COVID 19 Hypoxemic Respiratory Failure Residu $1,565,868 1 payment
3. Multicenter, Randomized Phase II study evaluating Pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma $1,368,734 10 payments
4. An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20 B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy $1,014,402 9 payments
5. Phase 1B Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma $992,878 196 payments
6. Multicenter randomized phase II trial of neoadjuvant radioimmunotherapy versus chemoimmunotherapy in patients with clinical stages IB-III (N2) non-small cell lung cancer $985,479 5 payments
7. An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) $967,823 11 payments
8. Magnetismm3 An Openlabel Multicenter Nonrandomized Phase 2 Study of Elranatamab Pf06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor One Immunomodulatory Drug and One Anticd38 Antibody $862,105 38 payments
9. Prcryo $848,413 4 payments
10. An Open-Label Study to Assess the Anti-Tumor Activity and Safety of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, in Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma $839,053 21 payments

1. Other $296,925 6 payments
2. Patient care $90,683 8 payments
3. Non-patient care $70,649 5 payments
4. Overhead $24,169 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.